CN114774327A - 一种植物乳杆菌hb13-2及其应用 - Google Patents
一种植物乳杆菌hb13-2及其应用 Download PDFInfo
- Publication number
- CN114774327A CN114774327A CN202210517712.5A CN202210517712A CN114774327A CN 114774327 A CN114774327 A CN 114774327A CN 202210517712 A CN202210517712 A CN 202210517712A CN 114774327 A CN114774327 A CN 114774327A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- health
- fermentation
- product
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 99
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 99
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 99
- 241000194019 Streptococcus mutans Species 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 230000036541 health Effects 0.000 claims abstract description 13
- 244000005700 microbiome Species 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 238000000855 fermentation Methods 0.000 claims description 19
- 230000004151 fermentation Effects 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 239000002068 microbial inoculum Substances 0.000 claims description 7
- 241000194026 Streptococcus gordonii Species 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000007413 intestinal health Effects 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 241000228245 Aspergillus niger Species 0.000 claims description 4
- 241000193755 Bacillus cereus Species 0.000 claims description 4
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000228150 Penicillium chrysogenum Species 0.000 claims description 4
- 241000228153 Penicillium citrinum Species 0.000 claims description 4
- 241001123663 Penicillium expansum Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 230000036737 immune function Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 235000008429 bread Nutrition 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000006041 probiotic Substances 0.000 abstract description 14
- 235000018291 probiotics Nutrition 0.000 abstract description 14
- 241000894006 Bacteria Species 0.000 abstract description 11
- 230000012010 growth Effects 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 241000194017 Streptococcus Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000000529 probiotic effect Effects 0.000 abstract description 2
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 12
- 230000003385 bacteriostatic effect Effects 0.000 description 11
- 210000000214 mouth Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- 102000016943 Muramidase Human genes 0.000 description 7
- 108010014251 Muramidase Proteins 0.000 description 7
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 229960000274 lysozyme Drugs 0.000 description 7
- 239000004325 lysozyme Substances 0.000 description 7
- 235000010335 lysozyme Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229920002444 Exopolysaccharide Polymers 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000007334 copolymerization reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 2
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 2
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241001149563 Streptococcus mutans ATCC 25175 Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- -1 naftidoxim Chemical compound 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Birds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及益生菌技术领域，具体涉及一种植物乳杆菌HB13‑2及其应用。本发明提供植物乳杆菌(Lactobacillus plantarum)HB13‑2，其保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No.23956。植物乳杆菌HB13‑2具有广谱的抑菌活性和良好的口腔定植能力，可显著抑制变异链球菌和戈氏链球菌以及常见食源性致病菌、腐败菌的生长，且对牙齿的腐蚀性弱，具备良好的口腔益生特性以及防腐保鲜的能力，在食品、保健品、日化用品、制药等领域具有广阔的应用前景，能够改善口腔亚健康状况，使用效果安全可靠。
Description
技术领域
本发明涉及益生菌技术领域，具体涉及一种植物乳杆菌及其应用。
背景技术
抗生素使用的最大弊端在于耐药菌株的产生，其次是药物残留、肠道菌群紊乱、内源性感染和二重感染、公共环境污染等一系列问题。抗生素的过度使用使得人类健康遭受威胁，已引起全球的广泛关注与重视。寻找绿色安全、高效无毒的抗生素替代品具有重要意义。
口腔微生物约有700余种，是人体的第二大微生物群落，与人体肠道菌群、呼吸道菌群有密切关系，对口腔以及身体健康具有重要作用。研究显示，口腔中存在部分有害微生物，可以生物膜形式附着在牙齿表面，诱发龋齿、牙龈炎、牙周炎等疾病，是口腔诸多健康问题的根源。此外，多项研究表明，口腔微生物与糖尿病、心血管疾、肿瘤等诸多全身性疾病相关。因此，口腔微生物是口腔健康的重要靶点。
益生菌是指活的微生物，当摄入足够数量时，对宿主起有益健康的作用。目前，益生菌应用于食品行业表现出巨大的潜力。益生菌在促进个体生长发育、增强机体免疫力、抗细菌感染、调节肠道微生态平衡等方面发挥重要作用，是一种理想的抗生素替代品。益生菌可以通过调节人体内正常菌群的平衡，从而起到抑制有害细菌、消炎、抗过敏、提高机体免疫力等作用。尤其，益生菌的诸多健康作用已在肠道疾病防治中得到了广泛验证，为口腔益生菌的开发提供了参考。益生菌作为微生态调节剂在口腔疾病防控方面具有安全高效的优势。目前，针对口腔益生菌的开发，国外已有报道；国内，尚处于起步阶段。因此，针对我国常见的龋齿等口腔疾病，选育具有我国自主知识产权的口腔益生菌，对打破国外垄断，开发具有我国自主知识产权的益生菌具有重要意义。
发明内容
本发明的目的是提供一种植物乳杆菌(Lactobacillus plantarum)HB13-2，该菌株具有耐酸、无溶血性、广谱抑菌、对抗生素敏感、对牙齿腐蚀性低、口腔定植能力高、抑制变异链球菌生物膜形成、高产胞外多糖以及改善肠道菌群和肠道健康的功能。
本发明提供植物乳杆菌(Lactobacillus plantarum)HB13-2，该菌株于2021年11月22日保藏于中国微生物菌种保藏管理委员会普通微生物中心(简称CGMCC，地址：北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所，邮编100101)，分类命名为植物乳杆菌Lactobacillus plantarum，保藏编号为CGMCC No.23956。
植物乳杆菌(Lactobacillus plantarum)HB13-2分离自河北省张家口市当地的传统酸菜食品中。
植物乳杆菌(Lactobacillus plantarum)HB13-2的微生物学特性如下：
(1)菌落形态：菌落乳白色圆形、中间略微隆起、不透明或半透明、边缘整齐。
(2)染色后细菌形态：革兰氏阳性，短杆状，无鞭毛，不运动。
(3)生长特性：在MRS液体培养基中，30-37℃培养，4h开始进入对数生长期，12h进入平台期。
所述植物乳杆菌(Lactobacillus plantarum)HB13-2 16S rDNA序列如SEQ IDNO.1所示。
本发明提供含有植物乳杆菌(Lactobacillus plantarum)HB13-2的菌剂，或含有植物乳杆菌(Lactobacillus plantarum)HB13-2发酵产物的菌剂。
本发明所述的菌剂可以为液体菌剂或固体菌剂，可采用常规技术手段、加入微生物制剂领域允许的辅料制备得到。
本发明还提供植物乳杆菌(Lactobacillus plantarum)HB13-2的发酵产物。
本发明还提供一种食品，其含有植物乳杆菌(Lactobacillus plantarum)HB13-2或由植物乳杆菌(Lactobacillus plantarum)HB13-2发酵制备得到。
本发明还提供一种药物，其含有植物乳杆菌(Lactobacillus plantarum)HB13-2或由植物乳杆菌(Lactobacillus plantarum)HB13-2发酵制备得到。
以上所述的药物具有如下功能中的任一种：
(1)抑制病原微生物和腐败微生物；
(2)抗肿瘤；
(3)治疗或缓解溃疡；
(4)调节免疫功能；
(5)降低胆固醇；
(6)改善肠道健康；
(7)改善口腔健康。
以上(1)中所述的病原微生物可为细菌或真菌。
在本发明的一种实施方式中，所述病原微生物和腐败微生物为金黄色葡萄球菌、蜡样芽孢杆菌、枯草芽孢杆菌、大肠杆菌、沙门氏菌、荧光假单胞菌、变异链球菌、戈氏链球菌、黑曲霉、桔青霉、产黄青霉和扩展青霉。
本发明提供所述植物乳杆菌(Lactobacillus plantarum)HB13-2或含有该菌的菌剂在制备食品、保健品、日化用品或药物中的应用。
所述食品为酸奶、饮料、馒头等中的一种或多种。
以上所述的应用中，所述保健品、日化用品或所述药物具有如下功能中的任一种：
(1)抑制病原微生物和腐败微生物；
(2)抗肿瘤；
(3)治疗或缓解溃疡；
(4)调节免疫功能；
(5)降低胆固醇；
(6)改善肠道健康；
(7)改善口腔健康。
以上(1)中所述的病原微生物可为细菌或真菌。
作为本发明的一种实施方式，所述病原微生物为金黄色葡萄球菌、蜡样芽孢杆菌、枯草芽孢杆菌、大肠杆菌、沙门氏菌、荧光假单胞菌、变异链球菌、戈氏链球菌、黑曲霉、桔青霉、产黄青霉和扩展青霉。
本发明通过实验证明，本发明提供的植物乳杆菌(Lactobacillus plantarum)HB13-2具有广谱抑菌活性，尤其能够抑制口腔致病菌，试验发现，24h时植物乳杆菌HB13-2和变异链球菌共聚能力达到67.40％，对变异链球菌生物膜形成抑制率为76.58％，植物乳杆菌HB13-2无溶血性，产酸性低，对牙齿腐蚀性低，具有较高抗生素敏感性和溶菌酶耐受性，并且高产胞外多糖。本发明为开发口腔益生以及防腐保鲜功能的食品、保健品以及日化用品等产品提供了新的菌株资源。
本发明的有益效果在于：本发明通过在传统酸菜中分离获得一株植物乳杆菌(Lactobacillus plantarum)HB13-2，该菌株能够耐酸、植物乳杆菌HB13-2具有广谱的抑菌活性和良好的口腔定植能力，安全性高，可显著抑制变异链球菌和戈氏链球菌以及常见食源性致病菌、腐败菌的生长，且对牙齿的腐蚀性弱，具备良好的口腔益生特性以及防腐保鲜的能力，在食品、保健品、日化用品、制药等领域具有广阔的应用前景，能够改善口腔亚健康状况，促进肠道健康，使用效果安全可靠。
附图说明
图1为本发明实施例1中植物乳杆菌(Lactobacillus plantarum)HB13-2的菌落形态图。
图2为本发明实施例1中植物乳杆菌(Lactobacillus plantarum)HB13-2的革兰氏染色图。
图3本发明实施例1中植物乳杆菌(Lactobacillus plantarum)HB13-2系统发育树示意图。
具体实施方式
以下实施例用于说明本发明，但不用来限制本发明的范围。
实施例1植物乳杆菌(Lactobacillus plantarum)HB13-2的分离与鉴定
1、菌株HB13-2的分离
挑选河北省张家口市当地的传统酸菜食品为样品稀释后，涂布于含有CaCO3的MRS固体培养基平板，静置，于30-37℃培养36-48h，挑选出有溶钙圈的疑似乳酸菌菌株，将分离菌株于MRS固体培养基培养24-48h后，观察发现菌落形态多呈乳白色圆形、中间略微隆起、不透明或半透明、边缘整齐(如图1所示)。
革兰氏染色呈阳性，菌体形态呈短杆，见图2。将初步确定的菌落在MRS固体培养基平板上反复划线几次，从而进一步进行纯化的目的，然后挑取单菌落于MRS培养基中30-37℃下培养至对数期，-40℃保藏备用。菌株命名为HB13-2。
2、对上述分离得到的菌株HB13-2进行16S rDNA鉴定将菌株HB13-2进行16S rDNA鉴定，(16S引物序列：细菌16S 27F：AGAGTTTGATCCTGGCTCAG；1492R：TACGGCTACCTTGTTACGACTT)结果显示该菌16S rDNA序列长度为1419bp，见SEQ ID NO.1。将测序结果与GenBank中的16S rDNA序列进行同源性比对，然后构建系统发育树(图3)，以确定菌株的种属关系。同源性分析结果表明，菌株HB13-2与Lactobacillus plantarum同源性达到100％，鉴定为植物乳杆菌，分类命名为植物乳杆菌Lactobacillus plantarum。
该菌株已于2021年11年22日保藏于中国微生物菌种保藏管理委员会普通微生物中心(简称CGMCC，地址：北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所，邮编100101)，分类命名为植物乳杆菌Lactobacillus plantarum，保藏编号为CGMCC No.23956。
实施例2植物乳杆菌(Lactobacillus plantarum)HB13-2的特性检测
种子液活化：将植物乳杆菌HB13-2接种到灭菌MRS液体培养基中，37℃厌氧静置14h后取出备用。
1、生长曲线测定
按1％接种量从种子液中吸取定量的植物乳杆菌HB13-2菌液接种到MRS液体培养基中，放入厌氧工作站中，37℃静置培养。每隔2h使用酶标仪测定发酵液在OD600的值，并保存各时间段的发酵液，进行活菌计数。
结果显示，植物乳杆菌HB13-2菌株在4h进入对数生长期，12h进入平台期，最大活菌数达到1.8×109CFU/mL。
2、植物乳杆菌HB13-2对变异链球菌和戈氏链球菌的抑菌性
指示菌的活化：取保存于河北科技大学食品与生物技术实验室的变异链球菌ATCC35668、变异链球菌ATCC25175、戈氏链球菌CGMCC1.2496于脑心浸液肉汤(BHI)培养基中30-37℃恒温箱中培养活化后，再将发酵液以1-3％的接种量于BHI培养基中，30-37℃培养至对数期，用紫外分光光度计调节菌悬液浓度为1×108CFU/mL，备用。
菌株抑菌特性评价：将上述指示菌以3％接种量接种到BHI固体培养基后倒平板。每个平板上等距离放3个无菌牛津杯。将保藏的植物乳杆菌HB13-2菌种于液体MRS培养基中30-37℃活化18-24h，之后按体积百分比1-3％接种量加入到液体MRS培养基，于30-37℃培养24-48h后，将100μL菌悬液以及发酵液离心后的上清液分别注入牛津杯，将平板放于4℃冰箱中预扩散后于30-37℃恒温培养箱中培养18-24h，观察抑菌效果，测量并记录抑菌圈的直径大小。进一步通过MIC测定试验发现，植物乳杆菌HB13-2上清液冻干粉对变异链球菌ATCC35668的MIC为15mg/mL，对戈氏链球菌CGMCC 1.2496的MIC为12mg/mL。
表1植物乳杆菌HB13-2对变异链球菌和戈氏链球菌的抑菌性
3、植物乳杆菌HB13-2与变异链球菌共聚能力检测
将植物乳杆菌HB13-2和变异链球菌乳酸菌37℃培养12h后，3000r/min离心10min收集菌体，用磷酸盐缓冲液洗涤并重悬分别制备菌悬液(植物乳杆菌HB13-2：OD600nm＝0.6；变异链球菌：OD600nm＝0.1)，将两株菌按照1:1的比例混匀后测定初始吸光值T0。吸取菌悬液1mL，37℃静置24h后测定上层混合菌液于600nm处的吸光度值Tt。共聚能力计算公式如下：
式中：T0—菌悬液初始OD600nm；Tt—静置后上层菌液OD600nm
24h时植物乳杆菌HB13-2和变异链球菌共聚能力达到67.40％，共聚能力强，说明植物乳杆菌HB13-2可降低变异链球菌的自凝集率，阻止其黏附定植于口腔中，并可通过唾液吞咽等行为将致病菌带离口腔。
4、植物乳杆菌HB13-2抑制变异链球菌生物膜的形成
将活化后的变异链球菌用BHI培养基调整菌体浓度为1.0×108CFU/mL用于生物膜的培养。在96孔板中加入100μL变异链球菌液和100μL15 mg/mL的植物乳杆菌HB13-2抑菌代谢产物，37℃培养48h后弃掉上层培养液，用PBS(0.01mol/L，pH＝7.2)溶液洗涤除去浮游菌。晾干后加入200μL质量浓度为0.1％的结晶紫溶液染色30min。吸弃多余染料，再用PBS溶液洗去浮色，晾干后加入95％乙醇溶液，酶标仪测定600nm处的吸光度值。植物乳杆菌HB13-2对变异链球菌生物膜形成抑制率为76.58％。
5、植物乳杆菌HB13-2广谱抑菌活性的验证
指示菌的活化：取保存于河北科技大学食品与生物技术实验室的大肠杆菌ATCC14028、金黄色葡萄球菌ATCC 25923、蜡样芽孢杆菌ATCC 11778、荧光假单胞菌ATCC 13525、枯草芽孢杆菌ATCC 13358于营养琼脂肉汤(NB)培养基中37℃恒温箱中培养活化后，再将发酵液以3％的接种量于NB培养基中，37℃培养至对数期，用紫外分光光度计调至菌悬液浓度为1×108CFU/mL，备用。桔青霉ATCC 9849、产黄青霉ATCC 10106、黑曲霉ATCC 16404、扩展青霉CICC 40658接种于马铃薯琼脂培养基PDA，30℃培养2-7d后，挑取孢子至生理盐水中，过滤并用血球计数法调至菌悬液浓度为105-106CFU/mL备用。
菌株抑菌特性评价：将上述细菌指示菌以3％接种量接种到NA培养基(真菌指示菌接种于PDA培养基)后倒平板。每个平板上等距离放3个无菌牛津杯。将保藏的植物乳杆菌HB13-2菌种于液体MRS培养基中37℃活化20h，之后按体积百分比3％接种量加入到液体MRS培养基，于37℃培养30h后，将发酵液离心后取上清液注入牛津杯，将平板放于4℃冰箱中预扩散后于37℃恒温培养箱中培养20h(真菌2d)，观察抑菌效果，测量并记录抑菌圈的直径大小。
表2植物乳杆菌HB13-2的抑菌谱
6、植物乳杆菌HB13-2溶血性的检测
向50-55℃的MRS固体培养基中加入无菌脱纤维羊血，混均后倒入培养皿中。待血琼脂培养基凝固后将稀释后的植物乳杆菌菌液均匀涂布到血平板上，37℃下培养30h观察植物乳杆菌HB13-2的菌落周围是否有透明圈出现。植物乳杆菌HB13-2无溶血性。由于菌体的溶血性会增加患败血症的危险，本试验结果显示植物乳杆菌HB13-2无溶血性，对机体安全。
7、植物乳杆菌HB13-2抗生素敏感性的验证
将植物乳杆菌HB13-2培养至对数期调节菌体浓度为1.0×108CFU/mL，HB13-2以3％添加量倒入50-55℃的MRS固体培养基中混合均匀并倒入培养皿中。待培养基凝固后将22种药敏纸片用无菌镊子均匀放置在平板上，37℃培养12h，观察记录透明圈直径，按照CLSI抗生素药物敏感性标准判定HB13-2抗生素敏感性。结果显示HB13-2对抗生素敏感性较高，具体对氨苄西林、氯霉素、呋喃妥因、阿莫西林、萘替米星、头孢吡肟、头孢噻肟7种抗生素敏感，对青霉素、卡那霉素、四环素、红霉素、新霉素、利福平、阿奇霉素7种抗生素中度敏感。
8、植物乳杆菌HB13-2的产酸性检测
将植物乳杆菌HB13-2培养至对数期调节菌体浓度为1.0×108CFU/mL，HB13-2以1％添加量加入到MRS液体培养基中，于37℃发酵48h后采用pH计测定植物乳杆菌发酵终点pH值。
采用pH计测定植物乳杆菌HB13-2发酵终点pH值判断HB13-2产酸性，筛选出产酸性较低的菌株。pH计测定HB13-2发酵终点pH值为3.98，产酸性低说明HB13-2对牙齿的危害小，可用于制备酸奶、乳饮料、馒头等食品的发酵剂。
9、植物乳杆菌HB13-2对牙齿腐蚀性的评价
采用酸-钼酸盐分光光度法考察植物乳杆菌HB13-2对牙齿腐蚀性。取3mL发酵36h的植物乳杆菌HB13-2发酵上清液和0.003g羟基磷灰石混合搅拌均匀后共同孵育，以变异链球菌发酵上清液为阳性对照。分别在1h、2h、3h、4h取等量孵育液离心(4700r/min，10min，4℃)，0h时为空白对照。取离心后的上清液(0.1mL)于试管中，加入2mL硫酸亚铁-钼酸铵溶液，再用超纯水定容至4mL，混合均匀，4700r/min离心10min。以磷标准溶液绘制标准曲线，测定620nm处吸光度值，根据标准曲线方程(y＝0.03355x+0.0202)计算磷质量浓度分析植物乳杆菌HB13-2对牙齿的腐蚀性。结果显示，4h时，与变异链球菌相比，植物乳杆菌HB13-2发酵上清液可使磷质量浓度相比较变异链球菌降低了6.005μg/mL，说明HB13-2对牙齿腐蚀性低。
10、植物乳杆菌HB13-2对溶菌酶耐受性的检测
将活化后的植物乳杆菌HB13-2培养到对数期调节菌体浓度为1.0×108CFU/mL，将50-55℃的MRS固体培养基和植物乳杆菌HB13-2菌液混合均匀后倒入培养皿，待培养基凝固后在培养皿中均匀放置牛津杯。将100μL的0-3mg/mL不同终浓度的溶菌酶溶液分别加入到牛津杯中，37℃过夜培养，测量各孔抑菌圈直径，以无抑菌圈出现的溶菌酶浓度为植物乳杆菌对溶菌酶最高耐受量。结果显示，植物乳杆菌HB13-2能耐受1.2mg/mL溶菌酶，见表3，说明植物乳杆菌HB13-2抗逆性好，且具有优良的口腔耐受性。
表3植物乳杆菌HB13-2对溶菌酶耐受性
11、植物乳杆菌HB13-2产胞外多糖的检测
将植物乳杆菌HB13-2培养36h后离心，取10mL发酵上清液和终浓度为8％的三氯乙酸混合，于4℃反应过夜。离心取上清液，加入三倍体积的无水乙醇沉淀多糖，反应沉淀即为粗胞外多糖。将粗胞外多糖经过8000-10000Da的透析袋于室温中过夜透析除掉单糖及其他杂质。采用苯酚-硫酸法测定乳酸菌产胞外多糖的能力。以葡萄糖标准溶液制作标准曲线，测定490nm处吸光度值，根据标准曲线方程(y＝7.17x+0.034)计算植物乳杆菌HB13-2胞外多糖含量，植物乳杆菌HB 13-2胞外多糖产量在283mg/L。
虽然，上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
序列表
<110> 河北科技大学
<120> 一种植物乳杆菌HB13-2及其应用
<130> KHP221115038.3
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1419
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
caggacgaac gctggcggcg tgcctaatac atgcaagtcg aacgaactct ggtattgatt 60
ggtgcttgca tcatgattta catttgagtg agtggcgaac tggtgagtaa cacgtgggaa 120
acctgcccag aagcggggga taacacctgg aaacagatgc taataccgca taacaacttg 180
gaccgcatgg tccgagtttg aaagatggct tcggctatca cttttggatg gtcccgcggc 240
gtattagcta gatggtgggg taacggctca ccatggcaat gatacgtagc cgacctgaga 300
gggtaatcgg ccacattggg actgagacac ggcccaaact cctacgggag gcagcagtag 360
ggaatcttcc acaatggacg aaagtctgat ggagcaacgc cgcgtgagtg aagaagggtt 420
tcggctcgta aaactctgtt gttaaagaag aacatatctg agagtaactg ttcaggtatt 480
gacggtattt aaccagaaag ccacggctaa ctacgtgcca gcagccgcgg taatacgtag 540
gtggcaagcg ttgtccggat ttattgggcg taaagcgagc gcaggcggtt ttttaagtct 600
gatgtgaaag ccttcggctc aaccgaagaa gtgcatcgga aactgggaaa cttgagtgca 660
gaagaggaca gtggaactcc atgtgtagcg gtgaaatgcg tagatatatg gaagaacacc 720
agtggcgaag gcggctgtct ggtctgtaac tgacgctgag gctcgaaagt atgggtagca 780
aacaggatta gataccctgg tagtccatac cgtaaacgat gaatgctaag tgttggaggg 840
tttccgccct tcagtgctgc agctaacgca ttaagcattc cgcctgggga gtacggccgc 900
aaggctgaaa ctcaaaggaa ttgacggggg cccgcacaag cggtggagca tgtggtttaa 960
ttcgaagcta cgcgaagaac cttaccaggt cttgacatac tatgcaaatc taagagatta 1020
gacgttccct tcggggacat ggatacaggt ggtgcatggt tgtcgtcagc tcgtgtcgtg 1080
agatgttggg ttaagtcccg caacgagcgc aacccttatt atcagttgcc agcattaagt 1140
tgggcactct ggtgagactg ccggtgacaa accggaggaa ggtggggatg acgtcaaatc 1200
atcatgcccc ttatgacctg ggctacacac gtgctacaat ggatggtaca acgagttgcg 1260
aactcgcgag agtaagctaa tctcttaaag ccattctcag ttcggattgt aggctgcaac 1320
tcgcctacat gaagtcggaa tcgctagtaa tcgcggatca gcatgccgcg gtgaatacgt 1380
tcccgggcct tgtacacacc gcccgtcaca ccatgagag 1419
<210> 2
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
agagtttgat cctggctcag 20
<210> 3
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
tacggctacc ttgttacgac tt 22
Claims (10)
1.植物乳杆菌(Lactobacillus plantarum)HB13-2，其特征在于，其保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No.23956。
2.根据权利要求1所述的植物乳杆菌(Lactobacillus plantarum)HB13-2，其特征在于，所述植物乳杆菌(Lactobacillus plantarum)HB13-2 16S rDNA序列如SEQ ID NO.1所示。
3.一种菌剂，其特征在于，含有权利要求1或2所述的植物乳杆菌(Lactobacillusplantarum)HB13-2或其发酵产物。
4.一种食品，其特征在于，含有权利要求1或2所述的植物乳杆菌(Lactobacillusplantarum)HB13-2或由权利要求1或2所述的植物乳杆菌(Lactobacillus plantarum)HB13-2发酵制备得到。
5.一种药物，其特征在于，含有权利要求1或2所述的植物乳杆菌(Lactobacillusplantarum)HB13-2或由权利要求1或2所述的植物乳杆菌(Lactobacillus plantarum)HB13-2发酵制备得到。
6.根据权利要求5所述的药物，其特征在于，所述药物具有如下功能中的任一种：
(1)抑制病原微生物和腐败微生物；
(2)抗肿瘤；
(3)治疗或缓解溃疡；
(4)调节免疫功能；
(5)降低胆固醇；
(6)改善肠道健康；
(7)改善口腔健康。
7.根据权利要求6所述的药物，其特征在于，所述病原微生物和腐败微生物包括金黄色葡萄球菌、蜡样芽孢杆菌、枯草芽孢杆菌、大肠杆菌、沙门氏菌、荧光假单胞菌、变异链球菌、戈氏链球菌、黑曲霉、桔青霉、产黄青霉和扩展青霉。
8.权利要求1或2所述的植物乳杆菌(Lactobacillus plantarum)HB13-2或权利要求3所述的菌剂在制备食品、保健品、日化用品或药物中的应用。
9.根据权利要求8所述的应用，其特征在于，所述保健品、日化用品或所述药物具有如下功能中的任一种：
(1)抑制病原微生物和腐败微生物；
(2)抗肿瘤；
(3)治疗或缓解溃疡；
(4)调节免疫功能；
(5)降低胆固醇；
(6)改善肠道健康；
(7)改善口腔健康。
10.根据权利要求8所述的应用，其特征在于，所述食品为酸奶、饮料、馒头中的一种或多种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210517712.5A CN114774327B (zh) | 2022-05-12 | 2022-05-12 | 一种植物乳杆菌hb13-2及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210517712.5A CN114774327B (zh) | 2022-05-12 | 2022-05-12 | 一种植物乳杆菌hb13-2及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114774327A true CN114774327A (zh) | 2022-07-22 |
| CN114774327B CN114774327B (zh) | 2023-08-15 |
Family
ID=82437329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210517712.5A Active CN114774327B (zh) | 2022-05-12 | 2022-05-12 | 一种植物乳杆菌hb13-2及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114774327B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115612637A (zh) * | 2022-07-26 | 2023-01-17 | 山西省生物研究院有限公司 | 一株植物乳杆菌及其应用 |
| CN116656577A (zh) * | 2023-07-25 | 2023-08-29 | 内蒙古大学 | 一种植物乳杆菌胞外多糖及其在制备免疫佐剂中的应用 |
| CN118345015A (zh) * | 2024-06-18 | 2024-07-16 | 青岛诺和诺康生物科技有限公司 | 一株发酵粘液乳杆菌及其制备改善口腔健康产品中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101974449A (zh) * | 2010-09-13 | 2011-02-16 | 郑州大学 | 一株植物乳杆菌及其应用 |
| EP2777405A1 (en) * | 2013-03-13 | 2014-09-17 | OrganoBalance GmbH | Novel Lactobacillus strains and the uses thereof |
| CN104845904A (zh) * | 2015-02-27 | 2015-08-19 | 河北科技大学 | 一种植物乳杆菌菌株及其应用 |
| CN112998172A (zh) * | 2021-04-16 | 2021-06-22 | 江南大学 | 红枣山楂复合饮料及其制备方法 |
-
2022
- 2022-05-12 CN CN202210517712.5A patent/CN114774327B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101974449A (zh) * | 2010-09-13 | 2011-02-16 | 郑州大学 | 一株植物乳杆菌及其应用 |
| EP2777405A1 (en) * | 2013-03-13 | 2014-09-17 | OrganoBalance GmbH | Novel Lactobacillus strains and the uses thereof |
| CN104845904A (zh) * | 2015-02-27 | 2015-08-19 | 河北科技大学 | 一种植物乳杆菌菌株及其应用 |
| CN112998172A (zh) * | 2021-04-16 | 2021-06-22 | 江南大学 | 红枣山楂复合饮料及其制备方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115612637A (zh) * | 2022-07-26 | 2023-01-17 | 山西省生物研究院有限公司 | 一株植物乳杆菌及其应用 |
| CN116656577A (zh) * | 2023-07-25 | 2023-08-29 | 内蒙古大学 | 一种植物乳杆菌胞外多糖及其在制备免疫佐剂中的应用 |
| CN116656577B (zh) * | 2023-07-25 | 2023-09-26 | 内蒙古大学 | 一种植物乳杆菌胞外多糖及其在制备免疫佐剂中的应用 |
| CN118345015A (zh) * | 2024-06-18 | 2024-07-16 | 青岛诺和诺康生物科技有限公司 | 一株发酵粘液乳杆菌及其制备改善口腔健康产品中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114774327B (zh) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114774327B (zh) | 一种植物乳杆菌hb13-2及其应用 | |
| CN112522134B (zh) | 一株凝结芽孢杆菌及其应用 | |
| CN112143680B (zh) | 具有抗氧化功效副干酪乳杆菌zjuids05及其应用 | |
| CN112375696B (zh) | 一种驴乳源戊糖片球菌及其应用 | |
| CN110669690B (zh) | 一种表达群体感应信号分子ai-2的植物乳杆菌菌株及其应用 | |
| CN112812999B (zh) | 一株对阴沟肠杆菌具有抑制作用的植物乳杆菌slb01及其衍生产品和应用 | |
| CN114642686B (zh) | 一种复合益生菌及其延缓衰老和抗氧化的作用 | |
| CN117143767B (zh) | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 | |
| CN106754584A (zh) | 用于高产细菌素的植物乳杆菌swun5815及其应用 | |
| CN114958658B (zh) | 一株抑制幽门螺旋杆菌的鼠李糖乳杆菌a21149及其应用 | |
| CN114774326A (zh) | 一株植物乳杆菌及其应用 | |
| CN110129220A (zh) | 一种保加利亚乳杆菌bsts6-4及其应用 | |
| CN116970512A (zh) | 一种植物乳杆菌、植物乳杆菌的培养方法及其应用 | |
| CN113249244B (zh) | 一种拮抗咽炎致病菌乙型溶血性链球菌的副干酪乳杆菌 | |
| CN103013893A (zh) | 一株植物乳杆菌ccl67及其应用 | |
| CN112852685B (zh) | 一株植物乳杆菌sal及其制剂、应用 | |
| CN112538448B (zh) | 一种从雪莲菌中定向筛选的具有益生特性的乳酸菌、筛选方法和应用 | |
| CN117660253A (zh) | 一种鼠李糖乳酪杆菌fmbl l23004 cnn、酸奶发酵剂、酸奶及其应用 | |
| US12077749B2 (en) | Bifidobacterium longum subsp. infantis with fimbriae and applications thereof | |
| CN117683670A (zh) | 一种植物乳植杆菌fmbl l23036 cnn、酸奶发酵剂、酸奶及其应用 | |
| CN117327616A (zh) | Lactiplantibacillus plantarum ZN1及其应用 | |
| KR20130032558A (ko) | 병원성 세균을 저해하는 유산균 및 이를 함유하는 조성물 | |
| CN110106113B (zh) | 一株高加索酸奶乳杆菌msr101及其应用 | |
| KR20110009516A (ko) | 신규한 락토바실러스 살리바리우스 균주 및 이를 함유하는 사료첨가제 조성물 | |
| CN113913334B (zh) | 一株粪肠球菌ef-za1107-06及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |